Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 12, 2014, Pages 1633-1653

  Puig, L ^a   Lopez A ^a   Vilarrasa, E ^a   Garcia I ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Janssen Cilag SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO; USTEKINUMAB;

ARTICLE; ATTRIBUTABLE RISK; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TREATMENT FAILURE; EUROPEAN UNION; HUMAN; META ANALYSIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; PSORIASIS; SEVERITY OF ILLNESS INDEX;

HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84911936567     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12238     Document Type: Article

References (38)

1. Heydendael VM, Spuls PI, Opmeer BC, et al,. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. New Engl J Med 2003; 349: 658-665.
2. Roberson ED, Bowcock AM,. Psoriasis genetics: breaking the barrier. Trends Genet 2010; 26: 415-423.
3. De Korte J, Sprangers MA, Mombers FM, et al,. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 225-230.
4. Pathirana D, Ormerod AD, Saiag P, et al,. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
5. Griffiths C, Strober B, Van de Kerkhof P, et al,. Comparison of ustekinumab and etanercept for moderate to severe psoriasis. N Engl J Med 2010; 362: 118-128.
6. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A,. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 274-285.
7. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W,. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-526.
8. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A,. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009; 219: 209-218.
9. Reich K, Burden AD, Eaton JN, Hawkins NS,. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-188.
10. Lucka TC, Pathirana D, Sammain A, et al,. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 2012; 26: 1331-1344.
11. Lin VW, Ringold S, Devine EB,. Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis: a Bayesian Network Meta-analysis. Arch Dermatol 2012; 15: 1-8.
12. Ferrándiz C, García A, Blasco AJ, Lázaro P,. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 768-777.
13. Puig L,. Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis. J Eur Acad Dermatol Venereol 2013; 27: e257-e260.
14. Gottlieb A, Matheson R, Lowe N, et al,. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632.
15. Reich K, Nestle F, Papp K, et al,. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366 (9494): 1367-1374.
16. Higgins J, Thompson S,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539e58.
17. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. URL www.cochrane-handbook.org (last accessed: 22 December 2012).
18. Leonardi CL, Powers JL, Matheson RT, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
19. Papp KA, Tyring S, Lahfa M, et al,. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
20. Tyring S, Gottlieb A, Papp K, et al,. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 36: 29-35.
21. van de Kerkhof PC, Segaert S, Lahfa M, et al,. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177-1185.
22. Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA,. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 661-668.
23. Gottlieb AB, Leonardi C, Kerdel F, et al,. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 652-660.
24. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB,. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357 (9271): 1842-1847.
25. Gottlieb AB, Evans R, Li S, et al,. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542.
26. Menter A, Feldman S, Weinstein G, et al,. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to- severe plaque psoriasis. J Am Acad Dermatol. 2007; 56: 31.e1-31.e15.
27. Gordon K, Langley R, Leonardi C, et al,. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open- label extension study. J Am Acad Dermatol 2006; 55: 598-606.
28. Saurat JH, Stingl G, Dubertret L, et al,. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158 (3): 558-566.
29. Menter A, Tyring S, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58 (1): 106-115.
30. Leonardi C, Kimball A, Papp K, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial PHOENIX 1. Lancet 2008; 371: 1665-1674.
31. Papp K, Langley R, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial PHOENIX 2. Lancet 2008; 371: 1675-1684.
32. Sterry W, Ortonne JP, Kirkham B, et al,. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010 Feb; 2 (340): c147.
33. Strohal R, Puig L, Chouela E, et al,. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat 2013; 24: 169-178.
34. Barker J, Hoffmann M, Wozel G, et al,. Efficacy and safety of infliximab vs. methotrexate in patients with moderate to severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE 1). Br J Dermatol 2011; 165: 1109-1117.
35. Thaci D, Ortonne P, Chimenti S, et al,. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163: 402-411.
36. NICE Technology appraisal, Psoriasis-ustekinumab (TA180). Ustekinumab for the treatment of adults with moderate to severe psoriasis. 2009. reviewed on January 2010. URL http://www.nice.org.uk/nicemedia/pdf/TA180Guidance.pdf (last accessed: 22 December 2012).
37. Puig L, Daudén E, Carrascosa JM,. Commentary on European and British guidelines for the treatment of psoriasis. Actas Dermosifiliogr 2010; 101: 285-290.
38. Kuhn A, Luger TA,. Psoriasis: is ustekinumab superior to etanercept for psoriasis? Nat Rev Rheumatol 2010; 6: 500-501.